Cross-Entity Comparative Takeaway

Pfizer dominates the lobbying dimension with 563 graph-linked records — nearly double Eli Lilly's 313 [1–6 vs. 27–31] and UnitedHealth's 318 [17–19] — and its 519 SEC filings [7–12] similarly lead the field, signaling the largest combined regulatory-and-capital-markets footprint of the four entities. Goldman Sachs presents the sharpest structural contrast: despite a comparatively modest 233 lobbying records [45–50], it carries the highest securities filing count outside Pfizer at 453 [51–56] and is the only entity with meaningful legislative exposure, with 20 graph-linked bill records [57–60] — a pattern consistent with financial-sector legislative engagement on tax, labor, and market-structure issues rather than drug-pricing or benefits regulation. Eli Lilly's 8 rulemaking records [38–41] and Pfizer's 24 [13–16] reflect active FDA regulatory-review periods for named drug products, while Goldman's 2 rulemaking records include a notable DOL proposed exemption filing ^[61], a discrete but non-trivial item. Assessment: UnitedHealth's profile is the leanest on non-lobbying dimensions — zero retrieved rulemaking, zero legislation — yet its single enforcement record ^[26] (*Ryan S. v. UnitedHealth Group*) is a confirmed, graph-linked case worth monitoring for benefits-litigation precedent, whereas Goldman's enforcement record ^[63] names an unrelated board defendant and is an unverified lead requiring docket confirmation before any exposure conclusion is drawn. None of the four entities show FARA or exclusion records in this sample, but absence here reflects the cap, not a clean record.

*The grid is a capped sample led by true graph counts; name-match columns (SEC/CFPB enforcement, certain rulemaking hits) are unverified leads, not confirmed exposure.*